Loading...
•
Feb 28, 2023
Walgreens Q2 2023 Earnings Report
Walgreens' financial results were in line with expectations, and the company remained on track with its full-year guidance.
Key Takeaways
Walgreens Boots Alliance reported a 3.3% increase in sales to $34.9 billion, but experienced a decrease in EPS to $0.81 and adjusted EPS to $1.16, impacted by lower COVID-19 vaccine and testing volumes. The company invested in VillageMD's acquisition of Summit Health and maintained its full-year adjusted EPS guidance.
Second quarter sales increased 3.3 percent year-over-year to $34.9 billion.
EPS decreased 20.3 percent to $0.81, and adjusted EPS decreased 27.2 percent to $1.16.
Invested $3.5 billion in VillageMD’s acquisition of Summit Health.
Maintaining full-year adjusted EPS guidance of $4.45 to $4.65.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Walgreens is maintaining its full-year adjusted EPS guidance of $4.45 to $4.65, with expectations of strong core business growth being offset by lapping peak COVID-19 demand. The company anticipates pivoting to mid-twenties percent adjusted EPS growth in the second half of fiscal 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...